User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Revision as of 01:43, 23 August 2025

Revision as of 13:51, 23 August 2025

Line 1:

{{User:SDZeroBot/NPP sorting/header|count=2214|date=23 August 2025|ts=0113:4351, 23 August 2025 (UTC)}}

{| class="wikitable sortable"

Line 29:

| C

| data-sort-value=5697 | [[Special:Contribs/Noxoug1|Noxoug1]] (5697)

|

|-

| 2025-08-08

| [[Sozinibercept]] <small>(Pharmaceutical compound)</small>

| Sozinibercept was an [[investigational drug]] intended to be used to treat certain eye conditions such as wet [[age-related macular degeneration]] (AMD). It is administered [[Intravitreal injection|intravitreally]] in combination with other Anti-[[VEGF-A]] including [[aflibercept]], [[faricimab]], [[ranibizumab]], and [[bevacizumab]].

| Start

| data-sort-value=2571 | [[Special:Contribs/Mahmoudalrawi|Mahmoudalrawi]] (2571)

|

|-

Line 57 ⟶ 50:

| Start

| data-sort-value=374 | [[Special:Contribs/Hoffmacs|Hoffmacs]] (374)

|

|-

| 2025-08-12

| [[Erbium(III) sulfate]] <small>(Chemical compound)</small>

| Erbium(III) sulfate is an [[erbium]] compound with the [[chemical formula]] {{chem2|Er2(SO4)3}}. It is a pink crystalline salt, readily absorbing water to form an octahydrate. It is used as a [[Colourant|colorant]] in [[glass manufacturing]] and [[porcelain enamel]] glazes, as well as a [[dopant]] in the production of [[optical fiber]].

| Stub

| data-sort-value=506 | [[Special:Contribs/Slavxe|Slavxe]] (506)

|

|-

Line 78 ⟶ 64:

| C

| data-sort-value=5697 | [[Special:Contribs/Noxoug1|Noxoug1]] (5697)

|

|-

| 2025-08-11

| [[Plutonium(III) phosphate]] <small>(Chemical compound)</small>

| Plutonium(III) phosphate is an [[inorganic compound]] of [[plutonium]], with the molecular formula {{chem2|PuPO4}}. It is the trivalent plutonium salt of [[phosphoric acid]].

| Start

| data-sort-value=4129 | [[Special:Contribs/Laura240406|Laura240406]] (4129)

|

|-

| 2025-08-15

| [[Erbium(III) carbonate]] <small>(Chemical compound)</small>

| Erbium(III) carbonate is an [[erbium]] compound with the [[chemical formula]] {{chem2|Er2(CO3)3}}.

| Start

| data-sort-value=4129 | [[Special:Contribs/Laura240406|Laura240406]] (4129)

|

|-

Line 98 ⟶ 70:

| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].

| Start

| data-sort-value=8767987709 | [[Special:Contribs/Ramblersen2|Ramblersen2]] (8767987709)

|

|-

Line 115 ⟶ 87:

|

|-

| 2025-0805-2204

| [[Erythrocyte-based drug delivery]] <small>(Drug delivery method)</small>

| [[Optimized Multicolor Immunofluorescence Panel]]

| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.

| Optimized Multicolor Immunofluorescence Panel, abbreviation OMIP, was a series of standardized multi-color [[flow cytometry]] panel launched by International Society for Advancement of Cytometry (ISAC), published in the form of columns in ''[[Cytometry Part A]]''.

| Start

| data-sort-value=4852 | [[Special:Contribs/Htmlzycq|Htmlzycq]] (4852)

|

|-

| 2025-08-21

| [[Selnoflast]] <small>(Experimental NLRP3 inflammasome inhibitor for neurological conditions)</small>

| Selnoflast (development codes RO7486967, RG-6418, IZD334) is an experimental small-molecule drug developed by [[Hoffmann-La Roche]] for the treatment of neuroinflammatory conditions. It is an orally active, selective, and reversible inhibitor of the [[NLRP3 inflammasome]], a key component of the [[innate immune system]] involved in inflammatory responses.

| C

| data-sort-value=56976 | [[Special:Contribs/Noxoug1DrugDelivery2025|Noxoug1DrugDelivery2025]] (56976)

|

|-

| 2005-05-21

| [[Antineoplastic]] <small>(Class of drugs used to treat malignant tumors)</small>

| Antineoplastic agents, also known as anti[[cancer]] drugs or antineoplastic drugs, are medications used to treat [[Cancer|malignant tumors]]. These drugs work through various mechanisms to kill or inhibit [[cancer cell]]s to achieve the goal of treating malignant tumors.

| data-sort-value="A0"|FA

| data-sort-value=0 | [[Special:Contribs/63.193.126.34|63.193.126.34]]

|

|-

| 2025-08-22

| [[Zimei Bu]] <small>(researcher)</small>

| Zimei Bu, PhD is a protein chemist in the [[City College of New York]], where she is Professor of Chemistry and Biochemistry and Laboratory Director.

| StartStub

| data-sort-value=21 | [[Special:Contribs/Wang Walton|Wang Walton]] (21)

|

|-

| 2025-08-1423

| [[Colorist Society International]] <small>(International professional association for motion picture and television colorists)</small>

| [[Lariocidin]] <small>(Chemical compound)</small>

| The Colorist Society International (CSI; often styled Colorist Society) is a professional association for motion picture and television [[Color grading|colorists]]. Founded in 2016, the society advocates for the creative and technical contributions of colorists in film, television, and streaming, and provides education, community chapters, and professional standards for the craft.

| Lariocidin (abbreviated as LAR) is a naturally occurring lasso-shaped peptide antibiotic produced by soil-derived bacterium ''Paenibacillus'' sp. M2. It is the first lasso peptide reported to inhibit protein synthesis in bacteria through interactions with the [[Ribosome|ribosome]].

| C

| data-sort-value=1193 | [[Special:Contribs/TravinDDavidjohnson80|TravinDDavidjohnson80]] (1193)

|

|-

| 2025-08-22

| [[Rilzabrutinib]]

| Rilzabrutinib is an oral, reversible covalent inhibitor of [[Bruton's tyrosine kinase]], may increase [[platelet]] counts in patients with [[immune thrombocytopenia]] by means of dual mechanisms of action: decreased [[macrophage]] (Fcγ receptor)–mediated platelet destruction and reduced production of pathogenic [[autoantibodies]].

| Stub

| data-sort-value=290 | [[Special:Contribs/Kelu|Kelu]] (290)

|

|-

| 2025-05-04

| [[Erythrocyte-based drug delivery]] <small>(Drug delivery method)</small>

| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.

| C

| data-sort-value=6 | [[Special:Contribs/DrugDelivery2025|DrugDelivery2025]] (6)

|

|}

<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] ^{''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''} at 0113:4351, 23 August 2025 (UTC)</span>